KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to $38.8 million.

  • TherapeuticsMD's Liabilities and Shareholders Equity fell 2.23% to $38.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.2 million, marking a year-over-year decrease of 6.57%. This contributed to the annual value of $38.8 million for FY2024, which is 10.36% down from last year.
  • TherapeuticsMD's Liabilities and Shareholders Equity amounted to $38.8 million in FY2024, which was down 10.36% from $43.3 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's Liabilities and Shareholders Equity ranged from a high of $181.6 million in FY2020 and a low of $38.8 million during FY2024.
  • In the last 3 years, TherapeuticsMD's Liabilities and Shareholders Equity had a median value of $43.3 million in 2023 and averaged $57.5 million.
  • Data for TherapeuticsMD's Liabilities and Shareholders Equity shows a maximum YoY slumped of 52.12% (in 2023) over the last 5 years.
  • TherapeuticsMD's Liabilities and Shareholders Equity (Yearly) stood at $181.6 million in 2020, then declined by 6.68% to $169.5 million in 2021, then plummeted by 46.62% to $90.5 million in 2022, then slumped by 52.12% to $43.3 million in 2023, then dropped by 10.36% to $38.8 million in 2024.